Open an account

Edgewise Therapeutics

EWTX · NASDAQ

$39.75+$1.83 (+4.83%)TodayMarket closed ·
Prev close $37.92

About EWTX

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 146 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Employees
154
Headquarters
Boulder, Colorado
Listed
Mar 26, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
edgewisetx.com

EWTX key statistics

Market cap
4.32B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.58M
Volume
2.17M
Open price
$38.03
High today
$40.32
Low today
$37.88
52 Week high
$48.51
52 Week low
$14.68

Edgewise Therapeutics (EWTX) at a glance

As of Oct 20, 2026, Edgewise Therapeutics (EWTX) shares are priced at $39.75, giving the company a market cap of 4.32B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $37.88 and $40.32. The current price is 4.9% above the day's low and 1.4% below its high.

Volume so far is 2.17M shares, above the average of 1.58M shares a day.

Over the past year Edgewise Therapeutics has ranged from $14.68 to $48.51, and now sits 74% of the way up that range.

Edgewise Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.53 per share against an estimate of -$0.4794.

The average analyst price target is $53.04, 33.4% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

89%of 9 analyst ratings say Buy
  • Buy88.9%
  • Hold11.1%
  • Sell0.0%
Price target · 15 analystsAvg $53.04
Low
$36.36
Now
$39.75
High
$69.30

EWTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 6.5% on average.

  1. Q3 FY24: reported -$0.36 per share against an estimate of -$0.3789
  2. Q4 FY24: reported -$0.42 per share against an estimate of -$0.425
  3. Q1 FY25: reported -$0.43 per share against an estimate of -$0.4376
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.4238
  5. Q3 FY25: reported -$0.39 per share against an estimate of -$0.4055
  6. Q4 FY25: reported -$0.47 per share against an estimate of -$0.4445
  7. Q1 FY26: reported -$0.46 per share against an estimate of -$0.4964
  8. Q2 FY26: reported -$0.53 per share against an estimate of -$0.4794

EWTX news

  • Press releasePRNewswire

    Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

  • Press releasePRNewswire

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

  • Press releasePRNewswire

    Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

  • Press releasePRNewswire

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

  • Press releasePRNewswire

    Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

  • Press releasePRNewswire

    Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

  • Press releasePRNewswire

    Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Similar companies

Companies in the same industry as Edgewise Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.